Almanack Investment Partners’s Moderna MRNA Stock Holding History

Almanack Investment Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Buy	+3,194	New	+$165K	0.03%	277
2024 Q3	–	Sell	-6,361	Closed	-$755K	–	187
2024 Q2	$755K	Buy	+6,361	New	+$805K	0.13%	91
2023 Q2	–	Sell	-1,480	Closed	-$227K	–	173
2023 Q1	$227K	Sell	1,480 -3,650	-71%	-$602K	0.04%	151
2022 Q4	$921K	Sell	5,130 -9,448	-65%	-$1.54M	0.2%	56
2022 Q3	$1.72M	Buy	+14,578	New	+$2.21M	0.34%	41
2022 Q2	–	Sell	-2,379	Closed	-$410K	–	493
2022 Q1	$410K	Buy	2,379 +737	+45%	+$124K	0.04%	296
2021 Q4	$417K	Buy	1,642 +873	+114%	+$255K	0.03%	294
2021 Q3	$296K	Buy	+769	New	+$284K	0.03%	377

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Almanack Investment Partners's MRNA Position: Q2 2026 in Review

Almanack Investment Partners opened a new position in Moderna (MRNA) in Q2 2026: 3,194 shares worth $224K. The stake represents 0.03% of the portfolio and ranks #277 among its holdings. This is a return to the name: Almanack Investment Partners previously reported a position in MRNA as recently as Q2 2024.

Almanack Investment Partners first reported a position in MRNA in Q3 2021 and has held it in 8 quarters since. The position peaked at $1.72M in Q3 2022. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Almanack Investment Partners held 3,194 shares of Moderna worth $224K as of Q2 2026.
Moderna was a new Almanack Investment Partners position in Q2 2026.
Moderna made up 0.03% of Almanack Investment Partners's portfolio in Q2 2026, its #277 holding.
Almanack Investment Partners first reported a position in Moderna in Q3 2021 and has held it in 8 quarters since.
Almanack Investment Partners's Moderna position peaked at $1.72M in Q3 2022.
783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.